Intracarotid chemotherapy (ICCT) with etoposide and cisplatin in patients (pts) with poor prognosis HIV-related CNS non-Hodgkin's lymphoma (HIV-CNS-NHL) (Meeting abstract).

Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Intracarotid chemotherapy (ICCT) with etoposide and cisplatin in patients (pts) with poor prognosis HIV-related CNS non-Hodgkin's lymphoma (HIV-CNS-NHL) (Meeting abstract).

Proc Annu Meet Am Soc Clin Oncol; 12:A23 1993. Unique Identifier : AIDSLINE ICDB/93694423
Madajewicz S; Fuhrer J; Chowhan N; Roche P; Heller H; Steigbigel R; Mariuz P; Hentschel P; SUNY, Stony Brook, NY 11794

Abstract: Between January 1991 and December 1991, 5 pts with high-grade HIV-CNS-NHL and 1 pt with non-HIV-CNS-NHL entered on a protocol of ICCT (Cancer 67:2844-9, 1991). All HIV-positive pts were on AZT therapy at the time of CNS-NHL diagnosis. All of them had an active opportunistic infection (4-CMV retinitis, 2-PCP). One pt had performance status of 1, 2 pts had performance status of 3 and 2 pts had performance status of 4. One pt had CD4 count of 230 and 4 pts a count of less than 50. One pt had an active disseminated intravascular coagulopathy with a platelet count maintained at the level of 80,000 by aggressive concentrated platelet transfusions. Four pts had total WBC count of 1500-2000/mm3 and platelet count of 80,000-100,000/mm3. The pt with non-HIV-CNS-NHL had progressive high-grade lymphoma after whole-brain radiation and several different systemic CTs. Pts received 1-4 courses of ICCT. There were no toxicities related to ICCT. Results are presented in a table. ICCT seems to be a safe and very effective therapy for both HIV- and non-HIV-CNS-NHL. Accrual of pts will continue.

Keywords: Antineoplastic Agents, Combined/ADVERSE EFFECTS/*THERAPEUTIC USE Brain Neoplasms/*DRUG THERAPY Cisplatin/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS Etoposide/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS Human HIV Infections/*DRUG THERAPY *Infusions, Intra-Arterial Lymphoma, AIDS-Related/*DRUG THERAPY Prognosis ABSTRACT
931230
M93C0808

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .